Loading...
XNAS
SBFMW
Market cap6mUSD
Jun 06, Last price  
0.25USD
1D
-20.40%
1Q
53.13%
IPO
-59.17%
Name

Sunshine Biopharma Inc

Chart & Performance

D1W1MN
No data to show
P/E
P/S
0.03
EPS
Div Yield, %
Shrs. gr., 5y
231.05%
Rev. gr., 5y
340.11%
Revenues
35m
+44.75%
000000001,70800447,20021,12171,410228,4264,345,60324,092,78734,874,283
Net income
-5m
L+13.94%
-13,122-31,1050-537,382-556,202-707,952-2,491,483-1,934,210-1,652,908-3,496,687-1,040,236-2,156,155-1,461,440-897,683-12,765,265-26,744,440-4,506,044-5,134,116
CFO
-13m
L+42.80%
-3,122-27,533-10,225-348,325-297,299-393,054-564,398-538,595-867,644-314,182-543,520-512,806-495,798-657,299-1,829,128-5,248,358-8,775,111-12,531,180
Earnings
Aug 14, 2025

Profile

Sunshine Biopharma, Inc., a pharmaceutical and nutritional supplement company, focuses on the research and development of anticancer drugs. The company is developing Adva-27a, a GEM-difluorinated C-glycoside derivative of podophyllotoxin to treat leukemia, lymphoma, testicular, lung, brain, prostate, bladder, colon, ovarian, liver, and other forms of cancers, as well as kills multidrug resistant cancer cells, including pancreatic cancer, breast cancer, small-cell lung cancer, and uterine sarcoma cells; and SBFM-PL4, an anti-coronavirus treatment compound. It also offers Essential 9, a nutritional supplement tablet; and Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name, as well as develops and markets other science-based nutritional supplements. The company has a license agreement with the University of Georgia to advance the development of its anti-coronavirus lead compound, SBFM-PL4. Sunshine Biopharma, Inc. is headquartered in Pointe-Claire, Canada.
IPO date
Aug 15, 2008
Employees
46
Domiciled in
CA
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
34,874
44.75%
24,093
454.42%
4,346
1,802.41%
Cost of revenue
41,627
28,439
12,939
Unusual Expense (Income)
NOPBT
(6,752)
(4,346)
(8,594)
NOPBT Margin
Operating Taxes
(235)
395
233
Tax Rate
NOPAT
(6,518)
(4,742)
(8,827)
Net income
(5,134)
13.94%
(4,506)
-83.15%
(26,744)
109.51%
Dividends
Dividend yield
Proceeds from repurchase of equity
5,383
3,548
30,268
BB yield
-255.68%
-53.71%
-311.55%
Debt
Debt current
208
119
3,632
Long-term debt
1,697
1,197
1,284
Deferred revenue
(43)
Other long-term liabilities
43
Net debt
(7,782)
(14,977)
(18,540)
Cash flow
Cash from operating activities
(12,531)
(8,775)
(5,248)
CAPEX
(82)
(305)
Cash from investing activities
(2,321)
(656)
(14,619)
Cash from financing activities
9,290
3,426
39,465
FCF
(13,964)
(5,877)
(12,102)
Balance
Cash
9,687
16,292
21,826
Long term investments
1,630
Excess cash
7,943
15,088
23,239
Stockholders' equity
(69,854)
(63,181)
(59,214)
Invested Capital
94,307
85,046
84,743
ROIC
ROCE
EV
Common stock shares outstanding
702
12
8
Price
3.00
-99.45%
543.00
-57.58%
1,280.00
-81.75%
Market cap
2,105
-68.13%
6,606
-32.01%
9,715
6.06%
EV
(5,663)
(8,370)
(8,824)
EBITDA
(6,529)
(4,197)
(8,568)
EV/EBITDA
0.87
1.99
1.03
Interest
9
137
39
Interest/NOPBT